- Pluristem and Sosei CVC will establish a new corporation which will pursue the clinical development and
commercialization of PLX-PAD in Japan
- The first indication to be developed will be Critical Limb Ischemia (CLI)
- Japan’s regulatory agency has already agreed on the study design of a 75-patient clinical trial in CLI for
potential conditional marketing approval under an accelerated pathway
- Initial funds of $11 million will be invested into the new corporation by Sosei RMF1 and
partners
HAIFA Israel, TOKYO, Dec. 20, 2016 (GLOBE NEWSWIRE) -- Corporate Venture Capital Ltd., (Subsidiary of Sosei
Group Corporation, a Tokyo Stock Exchange Mothers listed company), and Pluristem Therapeutics Inc. (Nasdaq:PSTI), (TASE: PSTI), a leading developer of placenta-based
cell therapy products, today announced the signing of a binding term sheet for the establishment of a new Japanese corporation
(NewCo) for the clinical development and commercialization of Pluristem’s PLX-PAD cell therapy product in Japan. Following
completion of fund-raising, the parties plan to establish NewCo in Japan. Pluristem will own 35% of NewCo in return for its
contribution of a perpetual license to commercialize PLX-PAD for Critical Limb Ischemia (CLI) in Japan. All proprietary rights
related to PLX-PAD will be exclusively owned by Pluristem. Sosei CVC’s investment fund, Sosei RMF1, together with additional
Japanese investors, will raise and invest approximately $11 million, equivalent to approximately ¥1.3 billion, in return for
ownership of 65% of NewCo.
The first indication to be developed by NewCo will be CLI. The design of a 75-patient study of PLX-PAD in CLI
was previously agreed upon with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) under an accelerated regulatory pathway
for regenerative medicine. This single study may lead to early conditional marketing approval and early reimbursement. Future
marketing activities are planned to be undertaken by NewCo. The parties plan to enter into a definitive agreement no later than
March 31, 2017.
“We are pleased to partner with Sosei CVC to commercialize PLX-PAD in Japan. The development of our CLI program
through the accelerated regulatory pathway could allow a more rapid entrance into the sizeable Japanese market, as has been our
strategy,” stated Zami Aberman, Pluristem’s Chairman and CEO. “Our cooperation with Sosei CVC also creates the potential to develop
additional indications in this market, by drawing on our robust portfolio of cell therapy product candidates in development,” Mr.
Aberman added.
“We are eager to begin the joint development of PLX-PAD in critical limb ischemia with the goal of
commercialization, and believe that our cooperation could lead to an efficient and successful entry into Japan’s substantial
market,” said Toshimi Miyoshi, Director, Sosei CVC. “The NewCo is expected to be a meaningful investment by Sosei RMF1 into the
regenerative medicine space, and will support our goal to stimulate the biotechnology industry in Japan,” Miyoshi concluded.
About Japan’s Conditional Time-limited Approval for Regenerative Medicine Products
Japan’s Act on the Safety of Regenerative Medicine went into effect in November 2014. Its purpose is to facilitate faster
commercialization of cellular therapies and other regenerative medicine treatments. Per the Act, these therapies can receive
conditional, time-limited approval for marketing, and be eligible for reimbursement, upon proof of safety and a signal of
effectiveness but prior to verification of efficacy. Safety and efficacy need to be confirmed via collection of observational data
from treated patients after the conditional approval.
About Pluristem Therapeutics
Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy products. The Company has
reported robust clinical trial data in multiple indications for its patented PLX (PLacental eXpanded) cells and is entering
late-stage trials in several indications. The cell products release a range of therapeutic proteins in response to inflammation,
ischemia, hematological disorders, and radiation damage. PLX cell products are grown using the Company's proprietary
three-dimensional expansion technology. They are off-the-shelf, requiring no tissue matching prior to administration.
Pluristem has a strong intellectual property position; Company-owned and operated, GMP-certified manufacturing
and research facilities; strategic relationships with major research institutions; and a seasoned management team.
About Sosei CVC and RMF1
Sosei Corporate Venture Capital (Sosei CVC) is the corporate venture arm of Sosei Group Corporation, a Tokyo
Stock Exchange Mothers listed company. Along with its partners, Sosei CVC currently manages Sosei RMF1, a ¥2 billion fund
focusing on investing in companies with innovative regenerative medicine technology.
Safe Harbor Statement
This press release contains express or implied forward-looking statements within the Private Securities
Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, we are using forward-looking statements when we
discuss the establishment of a Japanese new corporation, our expected holdings in the new corporation and the investment of
approximately $11 million in the new corporation by Sosei RMF1 and additional partners; when we discuss the development and
marketing plans of the new corporation; when we discuss PLX-PAD’s potential eligibility for early conditional marketing approval,
and for reimbursement, following a single, PMDA-approved clinical trial; when we discuss the parties’ plan to enter into a
definitive agreement and the proposed date of execution of such agreement; when we discuss the potential of the accelerated
regulatory pathway to allow us a more rapid entrance into the sizeable Japanese market; and when we discuss the potential of our
cooperation with Sosei CVC to develop additional indications in the Japanese market. Further, although Pluristem has signed a
binding term sheet, it may not be successful in negotiating definitive documentation by the date expected or at all, and even if
successful, the transaction may not be completed if the conditions to closing are not met. These forward-looking statements and
their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of
factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking
statements. The following factors, among others, could cause actual results to differ materially from those described in the
forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or
successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be
validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or
attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may
develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not
translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of
human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to
timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting
from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in
such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any
revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence
of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to
Pluristem's reports filed from time to time with the Securities and Exchange Commission.
Contact: Karine Kleinhaus, MD, MPH Divisional VP, North America 1-914-512-4109 karinek@pluristem.com Efrat Kaduri Investor and Public Relations Manager 972-74-7108600 efratk@pluristem.com
